Factors affecting warfarin control in patients attending the warfarin clinic in the cardiac surgical center in Ahmed Ghasim hospital (2010) by Mohamed, Reem
ﺣﺮﻟﺍ ﻦﻤﺣﺮﻟﺍ ﷲﺍ ﻢﺴﺑﻢﻴ  
University of Khartoum 
Graduate College 
Medical and Health studies Board 
 
Factors affecting warfarin control in patients 
attending the warfarin clinic in the cardiac 
surgical center in Ahmed Ghasim hospital 
(2010) 
 
By 
Dr. Reem Mohamed Ramli Ahmed 
M.B.B.S (university of Khartoum 2002) 
 
A thesis submitted in partial fulfillment for the requirements of the 
degree of M.D in clinical pathology 
 
Supervisor 
Dr. Abdelsalam Ibrahim Bashir 
M.B.B.S university of Khartoum ,D.C.P University of London. 
Associate professor of pathology, university of Khartoum 
 
I 
 
Dedication 
 
 
To my big family: 
Dear father , dear mother and sisters 
To my small family: 
My husband Haytham, and sweet kid 
Mohamed 
 
 
 
 
 
II 
 
 
Acknowledgment 
 
          After finishing my study, I would like to express my thanks to my 
supervisor,Dr.A/salam Ibrahim Bashir for his continuous effort in helping 
me in revision and discussion of my study. 
          I also thank Dr.Anwar.A.Y.Kordafani for her ideas and her 
continuous encouragement. 
          I also thank staff of Ahmed Ghasim hospital for helping me in the 
analysis of the samples. 
           Lastly I thank my family who supported me and encouraged me to 
complete my study. 
III 
 
Abstract 
Background 
            Warfarin is a commonly used medication with a narrow therapeutic 
index. The initiation of warfarin requires consideration of a variety of 
factors, which include reviewing the indications and contraindications for 
this agent, performing a thorough clinical assessment along with a risk-
benefit analysis for anticoagulation, consideration of warfarin 
pharmacology, developing strategies to monitor the intensity of 
anticoagulation and for the detection of adverse events, and education of the 
patient. 
Design:  
                  Descriptive  prospective cross sectional study. 
Setting:  
                 This study held at the cardiac surgery and renal transplant center 
in Ahmed Ghasim Hospital. 
Objectives: 
                   The different factors which affect proper warfarin control the 
level of knowledge,and the degree of control  in one hundred patient were 
assessed 
Methodology: 
                   Patient knowledge about the warfarin dose, the time of 
administration, the effect of diet, drug interaction with warfarin and the 
incidence of complication were studied using a direct questionnaire  and the 
last INR was measured to identify the level of control. 
Results: 
              The results were compared to the results of a similar Sudanese 
study which was conducted at 2000 in the same hospital in the same number 
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of patients. In our study 38% of the patients were properly controlled having 
an INR within the therapeutic range, in contrast to the previous study when 
the number is 34%, 20% of our patients had good level of education 
regarding warfarin, compared to 16% in the previous study .60% of our 
patients did not received any education programme about warfarin, 71.4% of 
them were educated after starting the therapy. 60% of the patients were 
taking different medication with different interaction with warfarin.88% of 
the patients knew the different interaction of warfarin with different types of 
diet.70% of the population studied live far from the center outside Khartoum 
state. Only 2 of our patients were provided with the warfarin booklets, and 
they obtained it from another hospital, in the previous study 12 of the 
patients had the booklet and they obtained it from abroad. 36% of our 
patients suffered from bleeding, the commonest site was epistaxis, 36.2% 
from them had bleeding for several times, compared to12% in the previous 
study this reflects the bad control as 33% of our patients had prolonged INR, 
compared to one patient in the previous study. Only 2 of our patients 
suffered from one attack of cerebral thrombosis in the form of 
cerebrovascular accident. School education did not seem to affect warfarin 
control since in both educated and illiterate patients, the percentage of those 
who had controlled INR are similar. The optimum maintainace dose was 
found to be 3-5mg. 
Conclusion: 
                 From this study it was concluded after 10 years that more than 
half of the patients were not well controlled having an INR outside the 
therapeutic range, the most significant causes of poor control were lack of 
full education about the drug and the far residence from hospital and 
laboratories and the high cost of the INR investigation. Bleeding endangered 
a large number of our patients life. Thrombosis still seemed to be a rare 
complication.  
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 ﻣﺴﺘﺨﻠﺺ اﻟﺒﺤﺚ
 ﺧﻠﻔﻴﺔ
ﻳﺴﺘﺠﻮب اﻟﺒﺪء ﻓﻰ . اﻟﻮارﻓﺮﻳﻦ هﻮ ﻋﻘﺎر ﺷﺎﺋﻊ اﻷﺳﺘﻌﻤﺎل ﻟﻪ اﻟﻌﺪﻳﺪ ﻣﻦ اﻟﻔﻮاﺋﺪ واﻷﺿﺮار ﻘﺎرﻋ  
اﻋﻄﺎء هﺬا اﻟﻌﻘﺎر ﻣﻦ ﻗﺒﻞ اﻟﻄﺒﻴﺐ  ﻣﻮازﻧﺔ اﻷﺳﺒﺎب اﻟﻤﻠﺰﻣﺔ ﻷﻋﻄﺎﺋﻪ ﻣﻊ  اﻷﺳﺒﺎب اﻟﻤﺎﻧﻌﺔ ﻷﻋﻄﺎﺋﻪ، 
ﺋﻞ اﻟﻤﺘﺎﺑﻌﺔ و ﻣﻌﺮﻓﺔ اﻷﻋﺮاض زاﺋﺪا اﻟﻔﺤﺺ اﻟﺴﺮﻳﺮى اﻟﺸﺎﻣﻞ واﻟﻤﻌﺮﻓﺔ ﺑﻔﺎرﻣﻮآﻠﺠﻰ اﻟﻌﻘﺎر ووﺳﺎ
  .اﻟﺠﺎﻧﺒﻴﺔ ﺑﺎﻷﺿﺎﻓﺔ اﻟﻰ ﺗﻮﻋﻴﺔ وارﺷﺎد اﻟﻤﺮﻳﺾ
 ﻧﻮع اﻟﺪراﺳﺔ
 دراﺳﺔ ﻣﻘﻄﻌﻴﺔ وﺻﻔﻴﺔ 
 اﻟﻤﻜﺎن 
 ﻣﺮآﺰ ﺟﺮاﺣﺔ اﻟﻘﻠﺐ واﻟﻜﻠﻰ ﺑﻤﺴﺘﺸﻔﻰ أﺣﻤﺪ ﻗﺎﺳﻢ
 اﻷهﺪاف:
ﺗﻢ دراﺳﺔ ﻣﺪى ﻣﻌﺮﻓﺔ اﻟﻤﺮﻳﺾ  ﻗﻴﺎس ﻣﻌﺪل اﻟﺴﻴﻮﻟﺔ ودراﺳﺔ اﻟﻌﻮاﻣﻞ اﻟﻤﺨﺘﻠﻔﺔ اﻟﺘﻰ ﺗﺆﺛﺮ ﻋﻠﻴﻪ         
  .ﻟﻌﻘﺎرﺑﺎ
 اﻟﻮﺳﺎﺋﻞ
ﺗﻢ دراﺳﺔ ﻣﺪى ﻣﻌﺮﻓﺔ اﻟﻤﺮﻳﺾ ﺑﺎﻟﺠﺮﻋﺔ، زﻣﻦ اﻋﻄﺎﺋﻬﺎ،أﺛﺮ ﻧﻮﻋﻴﺔ اﻟﻐﺬاء و اﺳﺘﻌﻤﺎل اﻟﻌﻘﺎرات 
  آﻤﺎ ﺗﻢ  ﻗﻴﺎس ﻣﻌﺪل اﻟﺴﻴﻮﻟﺔ .ﻋﻦ ﻃﺮﻳﻖ اﻟﺴﺆال اﻟﻤﺒﺎﺷﺮ اﻟﻤﺨﺘﻠﻔﺔ وﻣﻌﺪل ﺣﺪوث اﻟﻤﻀﺎﻋﻔﺎت
 اﻟﻨﺘﺎﺋﺞ
ﻟﻤﺴﺘﺸﻘﻰ م ﻓﻰ ﻧﻔﺲ ا 0002ﺗﻢ  ﻣﻘﺎرﻧﺔ اﻟﻨﺘﺎﺋﺞ ﻣﻊ ﻧﺘﺎﺋﺞ دراﺳﺔ ﺳﺎﺑﻘﺔ أﺟﺮﻳﺖ  ﻓﻰ اﻟﻌﺎم             
ﻣﻦ اﻟﻤﺮﺿﻰ ﻟﺪﻳﻪ ﻓﺤﺺ ﺳﻴﻮﻟﺔ ﻓﻰ اﻟﻤﺴﺘﻮى اﻟﻤﻄﻠﻮب ﻣﻘﺎرﻧﺔ  %83. ﻋﻠﻰ ﻧﻔﺲ اﻟﻌﺪد ﻣﻦ  اﻟﻤﺮﺿﻰ
ﻓﻰ % 61ﻣﻦ اﻟﻤﺮﺿﻰ ﻟﺪﻳﻬﻢ ﻣﻌﺮﻓﺔ ﺟﻴﺪة ﺑﺎﻟﻌﻘﺎر ﻣﻘﺎرﻧﺔ ب% 02.  ﻓىﺎﻟﺪراﺳﺔ ﺳﺎﺑﻘﺔ% 43ب 
ﻣﻨﻬﻢ % 4.17ﻋﻦ اﻟﻮارﻓﺮﻳﻦ ، 4ﻣﻦ اﻟﻤﺮﺿﻰ ﻟﻢ ﻳﺘﻠﻘﻮا أىﺒﺮﻧﺎﻣﺞ ﺗﻌﻠﻴﻤﻰ % 06اﻟﺪراﺳﺔ اﻟﺴﺎﺑﻘﺔ ، 
ﻣﻦ اﻟﻤﺮﺿﻰ ﻳﺴﺘﺨﺪﻣﻮن ﻏﻘﺎرات أﺧﺮى ﻟﻬﺎ ﺗﺄﺛﻴﺮات % 06. اﻟﻮارﻓﺮﻳﻦ ﺗﻠﻘﻮا ﻣﻌﻠﻮﻣﺎت ﺑﻌﺪ اﻟﺒﺪء ﻓﻰ
ﻳﺴﻜﻨﻮن ﺑﻌﻴﺪا ﻋﻦ % 07.ﻟﺪﻳﻬﻢ دراﻳﺔ ﺑﺄﺛﺮ ﻧﻮﻋﻴﺔ اﻟﻐﺬاء ﻋﻠﻰ اﻟﻌﻘﺎر% 88.ﻣﺨﺘﻠﻔﺔ ﻋﻠﻰ اﻟﻮارﻓﺮﻳﻦ
ﻣﻦ ﻣﺴﺘﺸﻔﻰ  ﻣﺮﻳﻀﻴﻦ ﻓﻘﻂ ﻟﺪﻳﻬﻢ آﺘﻴﺐ اﻟﻮارﻓﺮﻳﻦ وﻗﺪ ﺗﺤﺼﻠﻮا ﻋﻠﻴﻪ.اﻟﻤﺴﺘﺸﻔﻰ ﺧﺎرج وﻻﻳﺔ اﻟﺨﺮﻃﻮم
ﻋﺎﻧﻮا ﻣﻦ اﻟﻨﺰﻳﻒ % 63.وﻗﺪ ﺗﺤﺼﻠﻮا ﻋﻠﻴﻪ ﻣﻦ اﻟﺨﺎرج ﻟﺪﻳﻬﻢ اﻟﻜﺘﻴﺐ% 21ﻓﻰ اﻟﺪراﺳﺔ اﻟﺴﺎﺑﻘﺔ .أﺧﺮ
ﻓﻰ اﻟﺪراﺳﺔ  21%ﻋﺎﻧﻮا ﻣﻦ اﻟﻨﺰﻳﻒ ﻟﻌﺪة ﻣﺮات ﻣﻘﺎرﻧﺔ ب% 2.63. .اﻷآﺜﺮﻳﺔ ﻓﻰ ﺻﻮرة رﻋﺎف
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ﻣﻦ اﻟﻤﺮﺿﻰ  ﻟﺪﻳﻪ ﻓﺤﺺ ﺳﻴﻮﻟﺔ أآﺜﺮ ﻣﻦ اﻟﻤﺴﺘﻮى اﻟﻤﻄﻠﻮب ﻣﻘﺎرﻧﺔ % 33اﻟﺴﺎﺑﻘﺔ  وذﻟﻚ ﻷن 
ﻣﺮﻳﻀﻴﻦ ﻓﻘﻂ ﺗﻌﺮﺿﻮا ﻟﺘﺠﻠﻂ اﻟﺪم ﻣﻤﺎ أدى اﻟﻰ ﺣﺪوث ﺟﻠﻄﺎت .ﺑﻤﺮﻳﺾ واﺣﺪ ﻓﻰ اﻟﺪراﺳﺔ اﻟﺴﺎﺑﻘﺔ
ﻓﺤﺺ ﺳﻴﻮﻟﺔ ﻓﻰ اﻟﻤﺴﺘﻮى اﻟﻤﻄﻠﻮب ﻋﻨﺪ اﻷﻣﻴﻦ واﻟﻤﺘﻌﻠﻤﻴﻦ  ﻧﺴﺒﺔ اﻟﻤﺮﺿﻰ اﻟﺬﻳﻦ ﻟﺪﻳﻬﻢ .دﻣﺎﻏﻴﺔ
  .ﻣﻠﺠﻢ 3-5اﻟﺠﺮﻋﺔ اﻟﻤﺜﺎﻟﻴﺔ ﻟﻠﻌﻘﺎر ﺗﺘﺮاوح ﺑﻴﻦ .ﻟﻤﺪرﺳﻰ ﻟﻴﺲ ﻟﺪﻳﻪ أﺛﺮﻣﺘﻘﺎرﺑﺔ ﻣﻤﺎ ﻳﺪل ﻋﻠﻰ أن اﻟﺘﻌﻠﻴﻢ ا
 اﻟﺨﻼﺻﺔ
أﻧﻪ ﺑﻌﺪ ﻋﺸﺮة ﺳﻨﻮات ﻻ ﻳﺰال أآﺜﺮ ﻣﻦ ﻧﺼﻒ اﻟﻤﺮﺿﻰ ﻟﺪﻳﻪ  ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ ﻧﺴﺘﺨﻠﺺ           
ﻓﺤﺺ ﺳﻴﻮﻟﺔ ﺧﺎرج اﻟﻤﺴﺘﻮى اﻟﻤﻄﻠﻮب واﻷﺳﺒﺎب هﻰ  ﻋﺪم وﺟﻮد ﺗﻮﻋﻴﺔ وارﺷﺎد ﻟﻠﻤﺮﺿﻰ 
ﻻ ﻳﺰال اﻟﻨﺰف ﻳﻬﺪد ﺣﻴﺎة .واﻟﻌﻼج ﺑﺎﻷﺿﺎﻓﺔ اﻟﻰ ﻏﻼء اﻟﻔﺤﺺ وﺳﻜﻨﻬﻢ ﺑﻌﻴﺪا ﻋﻦ أﻣﺎآﻦ اﻟﻔﺤﺺ
   .اﻟﻌﺪﻳﺪ ﻣﻦ اﻟﻤﺮﺿﻰ أﻣﺎ اﻟﺘﺠﻠﻂ ﻓﻼ ﻳﺰال ﻣﻦ اﻟﻤﻀﺎﻋﻔﺎت اﻟﻨﺎدرة
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Appendix(1) 
ﻢﻴﺣﺮﻟا ﻦﻤﺣﺮﻟا ﷲا ﻢﺴﺑ 
 Graduate college 
Medical and health studies board 
Serial No (   ) 
Name:………………………………………………………….. 
1.Sex :                  a. male            b. female 
2.Age: a.10-19  b. 20 29  c. 30-39 d. 40-49 e. 50-60 f>60 
3.Residence: a. near to the center b. far from the center 
4.Education:   a. illiterate     b. primary   c. intermediate d. secondary  e. 
graduate f. postgraduate 
5.Occupation: ..…………………………………………….. 
Patient warfarin therapy 
6.Indication for warfarin therapy 
7.Duration for warfarin therapy………………………………… 
8.Time of warfarin intake a. in the morning b. middy      c. evening   d. at 
any time during the day 
9.Dose of warfarin now…………………… 
10.1  No. of visit for  warfarin control: 
a. according to the doctor request       b. not regular 
10.2 if b. explain why?    
11.1 Dose the patient take any drug(s) other than warfarin?  
 a. yes      b. no 
11.2 . If (a) mention it( them)………………………………. 
12.1. Have you received education program about warfarin?  
a yes.       b. no 
12.2. If yes when ? 
     a. before initiation of warfarin    b. after  initiation of warfarin   
12.3 If yes where ?    a. private clinic.        b. hospital       c. abroad  
13.1 Have you warfarin booklet?   a. yes      b. no. 
13.2 If yes, from where did you obtain it? a. Sudan   b. abroad 
13.3 if yes are you taking it with you all the time? 
14. is there any difficulty in taking warfarin? 
a. not available in the nearby pharmacy 
b. expensive 
c. difficult to obtain the exact dose 
d. residence far away from the laboratories and hospitals 
e. other factors 
if ( e) mention these factors………………………………… 
Patient  knowledge about warfarin 
15. what is warfarin?   a. knows   b.  does not know   
16.  why are you on warfarin? a. knows   b. does not knows   
17. what is the type of warfarin tablets and its colour? 
a. knows all types by its dose and colour 
b. knows all types its colour only 
c.  knows 2 types by its dose and colour 
d. knows 2 types  by its colour only 
e. . knows 1 types  by its dose and colour 
f. knows 1 types colour only 
g. does not know 
18.1 does the patient  knows diet containing vit k  ?   a. yes   b.no. 
 18.2 if yes mention few………………………….. 
19.1 does the patient  knows that there is interactions between warfarin and  
19.1 antibiotics       a. yes      b. no 
19.2 asprin             a. yes      b. no 
20. What the patient will do if he/she is ill and needs antibiotics? 
a. goes to a doctor and tell him he/she on warfarin 
b .goes to a doctor and tell him he/she on warfarin if asked 
c. gets antibiotics from the nearby pharmacy  
21. What the patient will do if he/she is ill and needs any surgical or dental 
operation? 
 a. To inform the doctor and tell him he/she on warfarin 
 b. To inform the doctor and tell him he/she on warfarin if asked 
22. question to married women 
If you get  pregnant what  to do?  
a. to inform the doc tor that I am on warfarin. 
b. to continue the same dose 
Warfarin complications 
23.1  Have you ever have bleeding while you are on warfarin? 
                a.   yes.           b.no 
23.2  If a When?............................................................................... 
23.3   where is are the site(s) of that bleeding ? …………………… 
23.4   How many time?       A. once          b. twice c.> twice 
24.1  Have you any thrombotic attack while you are on warfarin? 
 a. yes  b. no 
24.2  If yes when?.......................................................................... 
24.3  Where is/ are the site (s) that thrombosis ?......................... 
24.4   Number of thrombotic attacks ? a. once    b. twice c.> twice 
24.5  If © specify…………………………………………………… 
Investigations   
25. last INR investigations…………………………………………   
 
    
 
 
  
 
 
 
 
 
 
 
Appendix(3) 
Agents that increase INR or bleeding risk  
1. Acetaminophen (Tylenol) 
2. Alcohol 
3. Amiodarone (Cordarone)   
              Adjustment per Amiodarone maintenance dose (7):  
1. Amiodarone 400 mg/day: Reduce Warfarin dose 
40%  
2. Amiodarone 300 mg/day: Reduce Warfarin dose 
35%  
3. Amiodarone 200 mg/day: Reduce Warfarin dose 
30%  
4. Amiodarone 100 mg/day: Reduce Warfarin dose 
25%  
4. Anabolic Steroids 
5. Antifungal Medications  
1. Fluconazole (Diflucan) 
2. Ketoconazole (Nizoral) 
3. Itraconazole (Sporanox) 
4. Miconazole (Monistat)  
6. Aspirin and Salicylates 
7. Cephalosporins  
1. Cefoperazone (Cefobid) 
2. Cefamandole (Mandol) 
3. Cefotetan (Cefotan) 
4. Cefmetazole (Zefazone)  
8. Chloral Hydrate 
9. Cimetidine (Tagamet) 
10. Clofibrate 
11. Cranberry Juice (CYP2C9 inhibitor) appears safe in at least one 
clinical trial (8). 
12. Danazol (Danocrine) 
13. Diflunisal (Dolobid) 
14. Disulfiram (Antabuse) 
15. Fluvoxamine (Luvox) 
16. Ginkgo Biloba (independent effect due to antiplatelet activity) 
17. Heparin 
18. HMG CoA Reductase inhibitors 
19. Isoniazid (INH) 
20. Macrolides  
1. Erythromycin 
2. Clarithromycin  
21. Metronidazole (Flagyl) 
22. Nalidixic Acid 
23. NSAIDs 
24. Omeprazole (Prilosec) 
25. Paroxetine (Paxil) 
26. Penicillin 
27. Propafenone (Rythmol) 
28. Quinidine 
29. Quinolones 
30. Sulfinpyrazone (Anturane) 
31. Tamoxifen 
32. Tetracycline 
33. Thyroid Hormone (Thyroxine or Synthroid) 
34. Ticlopidine (Ticlid) 
35. Trimethoprim-Sulfamethoxazole (Bactrim, Septra) 
36. Vitamin E  
Theoretical bleeding risk, but appears to be safe in clinical trials 
(9). 
Drugs that decrease INR or increase clotting risk  
37. American Ginseng (no effect on Warfarin with Asian Ginseng) 
38. Barbiturates 
39. Binding Resins 
40. Carbamazepine (Tegretol) 
41. Oral Contraceptives 
42. Penicillin 
43. Rifampin 
44. St. John's Wort 
45. Vitamin K  
Drugs that have variable effect on INR or bleeding risk  
46. Allopurinol 
47. Corticosteroids 
48. Phenytoin (Dilantin)  
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 ارﺷﺎدات ﻟﻤﺮﺿﻰ ﻋﻴﺎدة ﺳﻴﻮﻟﺔ اﻟﺪم ﻋﻦ ﻋﻘﺎر اﻟﻮارﻓﺮﻳﻦ
 
  .ﻓﻰ اﻟﺠﺴﻢ اﻟﺪﻣﻮﻳﺔ ﻓﻰ  ﻤﻨﻊ ﺣﺪوث اﻟﺠﻠﻄﺎتﻟ ﻟﺰﻳﺎدة ﺳﻴﻮﻟﺔ اﻟﺪم اﻟﻮارﻓﺮﻳﻦ ﻋﻘﺎرﻳﺴﺘﻌﻤﻞ  •
 اﻟﺘﻰ ﺗﺴﺘﺪﻋﻰ اﻟﻌﻼج ﺑﻌﻘﺎر اﻟﻮارﻓﺮﻳﻦأﻣﺜﻠﺔ ﻟﺒﻌﺾ اﻟﺤﺎﻻت  •
 ﺟﻠﻄﺎت ﻓﻰ أوردة اﻟﻘﺪﻣﻴﻦ              
 اﻟﺼﻤﺎﻣﺎت اﻟﻤﻌﺪﻧﻴﺔ                               
 اﻟﺬﺑﺤﺔ اﻟﺼﺪرﻳﺔ,ﻋﺪم اﻧﺘﻈﺎم ﺿﺮﺑﺎت اﻟﻘﻠﺐ  ﻣﻤﺎ ﻳﺆدى اﻟﻰ اﻟﺴﻜﺘﺔ اﻟﺪﻣﺎﻏﻴﺔ             
 .ﺟﻠﻄﺔ ﻓﻰ اﻟﺮﺋﺘﻴﻦ             
وﻳﺘﻢ ﺗﺤﺪﻳﺪ ,ﻟﻤﻌﺮﻓﺔ ﻧﺴﺒﺔ اﻟﺴﻴﻮﻟﺔ  ﺧﺎص ﻟﻠﺪم دورى ﻖ ﻓﺤﺺﻣﺘﺎﺑﻌﺔ اﻟﻌﻼج ﺗﺘﻢ ﻋﻦ ﻃﺮﻳ •
 .اﻟﺠﺮﻋﺔ ﻋﻠﻰ ﺿﻮء ﻧﺘﻴﺠﺔ هﺬا اﻟﻔﺤﺺ
 .اﻟﻨﺰف هﻮ أهﻢ اﻻﻋﺮاض اﻟﺠﺎﻧﺒﻴﺔ ﻟﻠﻌﻘﺎر •
 . اﻟﺴﻴﻮﻟﺔ ﺰف آﻠﻤﻞ زادت ﻧﺴﺒﺔﻳﺰداد اﺣﺘﻤﺎل اﻟﻨ •
 :اﻟﻨﺰف ﻳﻤﻜﻦ أن ﻳﻜﻮن ﻣﻦ  •
  ﺻﻮرة رﻋﺎف  ﻓѧѧѧѧѧﻰ اﻷﻧﻒ          
 ,ﻣﻦ اﻟﻠﺜﺔ ﻋﻨﺪ ﺗﻨﻈﻴﻒ اﻷﺳﻨﺎن          
 اﻟﻨﺰﻳﻒ اﻟﺠﻠﺪى ﻓﻰ ﺻﻮرة ﺑﻘﻊ ﺻﻐﻴﺮة أو آﺒﻴﺮة          
 اﻟﺪﻣﻮى أو اﻻﺳﺘﻔﺮاغ وﺟﻮد اﻟﺪم ﻓﻰ اﻟﺒﻮل أو اﻟﺒﺮاز          
  .ﻓﻰ  اﻟﺪورة اﻟﺸﻬﺮﻳﺔ اﻟﻤﻔﻘﻮد زﻳﺎدة آﻤﻴﺔ اﻟﺪم          
 .ﻋﻤﻠﻴﺔ ﺟﺮاﺣﻴﺔ ﻟﺘﻔﺎدى اﻟﻨﺰف أﺧﺒﺮ ﻃﺒﻴﺒﻚ أﻧﻚ ﺗﺴﺘﺨﺪم اﻟﻮارﻓﺎرﻳﻦ اذا آﻨﺖ ﻣﻘﺪﻣﺎ ﻋﻠﻰ •
 .أﻧﻚ ﺗﺴﺘﺨﺪم اﻟﻮارﻓﺎرﻳﻦ اﻟﻨﺰف أﺧﺒﺮ ﻃﺒﻴﺐ اﻷﺳﻨﺎن ﻟﺘﻔﺎدى  •
ﺿﻚ ﻓﻰ ﺣﺎﻟﺔ ﺣﺪوث اﻟﺤﻮادث او ﺗﻌﺮ ﻟﺘﻔﺎدى اﻟﻨﺰف أﺧﺒﺮ ﻃﺒﻴﺒﻚ أﻧﻚ ﺗﺴﺘﺨﺪم اﻟﻮارﻓﺎرﻳﻦ •
 .ﻷى ﻧﻮع ﻣﻦ اﻟﺠﺮوح
 .أﺣﺮص ﻋﻠﻰ ﺣﻤﻞ آﺘﻴﺐ اﻟﻮارﻓﺮﻳﻦ ﻣﻌﻚ ﻓﻰ آﻞ اﻷوﻗﺎت ﻟﺘﻔﺎدى اﻟﻨﺰف •
 :ص ﻋﻠﻰ اﻷﺗﻰﺮر أﺣﻟﻀﻤﺎن ﺳﻼﻣﺘﻚ أﺛﻨﺎء ﺗﻨﺎوﻟﻚ اﻟﻌﻘﺎ •
 .ﻣﻦ اﻟﻄﺒﻴﺐ ﻓﻘﻂ  ﻟﻚ ﺧﺬ اﻟﺠﺮﻋﺔ اﻟﻤﺨﺼﺼﺔ •
 .ﻳﻔﻀﻞ ﻓﻰ اﻟﻤﺴﺎء,ﺧﺬ اﻟﺠﺮﻋﺔ ﻣﺮة واﺣﺪة ﻓﻰ اﻟﻴﻮم •
 .اﺧﺒﺎر اﻟﻄﺒﻴﺐ اﻟﻤﺨﺘﺺ ﻓﻮرا ﻟﻠﺤﻤﻞ او ﻓﻰ ﺣﺎﻟﺔ ﺣﺪوث ﺣﻤﻞ ﻋﻠﻴﻚ ﻟﻠﻨﺴﺎء اذا آﻨﺖ ﺗﺨﻄﻄﻴﻦ •
 :ﺬﻟﻚﺗﺘﺄﺛﺮ ﻓﻌﺎﻟﻴﺔ اﻟﻌﻘﺎر ﺑﺎﻟﻌﺪﻳﺪ ﻣﻦ اﻟﻌﻮاﻣﻞ ﻣﺜﺎل ﻟ •
ﻟﺬﻟﻚ ,و اﻷﺳﺒﺮﻳﻦﺑﻌﺾ أﻧﻮاع اﻟﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ,ﻴﻨﺎتﻴﺘﺎﻣﺑﻌﺾ أﻧﻮاع اﻟﻌﻠﻼﺟﺎت ﻣﺜﻞ اﻟﻔ •
 .ﺟﺪﻳﺪ ﺠﺐ اﺳﺘﺸﺎرة ﻃﺒﻴﺒﻚ ﻋﻨﺪ ﺗﻨﺎوﻟﻚ اى ﻋﻼجﻳ
 ﻳﺘﺄﺛﺮ أﻳﻀﺎ ﺑﻨﻮﻋﻴﺔ اﻟﻐﺬاء •
 ﻣﻠﺠﻢ5اﻟﺰهﺮى ,ﻣﻠﺠﻢ 3اﻷزرق ,ﻣﻠﺠﻢ 1اﻟﺒﻨﻰ: ﻓﻰ ﺛﻼﺛﺔ أﻟﻮان اﻟﻮارﻓﺮﻳﻦ ﻳﺄﺗﻰ ﻏﻘﺎر  •
 .اﻟﻴﻮم ﻗﺖ ﺧﻼلﻓﻰ ﺣﺎﻟﺔ ﻧﺴﻴﺎن أﺧﺬ اﻟﺠﺮﻋﺔ ﻓﻰ اﻟﻮﻗﺖ اﻟﻤﺤﺪد أﺧﺬهﺎ ﻓﻰ أى و •
ﻣﻦ اﻟﻤﺨﺎﻃﺮة   ,ﺬ اﻟﺠﺮﻋﺔ اﻟﻤﻘﺮرة ﻓﻘﻂ ﻟﺬﻟﻚ اﻟﻴﻮمﻓﻰ ﺣﺎﻟﺔ ﻧﺴﻴﺎن ﺟﺮﻋﺔ اﻟﻴﻮم اﻟﺴﺎﺑﻖ ﻗﻢ ﺑﺄﺧ  •
  .اﻟﺠﺮﻋﺔ ﺔﻀﺎﻋﻔﻣ
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Introduction 
 
 
           The name warfarin stems from the acronym for the organization which 
funded the key research, WARF, for Wisconsin Alumni Research Foundation + 
the ending -arin indicating its link with coumarin (1). Warfarin is a synthetic 
derivative of the naturally occurring anti-coagulant dicumarol. The anti-coagulant 
properties of dicumarol were first observed in cattle that suffered a hemorrhagic 
disorder after being fed spoiled sweet clover hay during the 1920s. Karl Link 
identified the causative agent by 1939 and later developed warfarin as a rat 
poison before it was used in humans in the 1950s. However the anticoagulant 
mechanism of warfarin was not elucidated until twenty years later (2). 
 
          Warfarin is a commonly used medication with a narrow therapeutic 
index. The initiation of warfarin requires consideration of a variety of factors, 
which include reviewing the indications and contraindications for this agent, 
performing a thorough clinical assessment along with a risk-benefit analysis for 
anticoagulation, consideration of warfarin pharmacology, developing strategies 
to monitor the intensity of anticoagulation and for the detection of adverse 
events, and education of the patient (3).  
  
 
 
 
Mechanism of Action of Coumarin  
          Warfarin, a coumarin derivative, produces an anticoagulant effect 
by interfering with the cyclic interconversion of vitamin K and its 2,3 epoxide 
(vitamin K epoxide). Vitamin K is a cofactor for the carboxylation of glutamate 
residues to carboxyglutamates (Gla) on the N-terminal regions of vitamin K–
dependent proteins (3). These proteins , which include the coagulation factors 
II, VII, IX, and X, require carboxylation by vitamin K for biological activity. 
By inhibiting the vitamin K conversion cycle, warfarin induces hepatic 
production of partially decarboxylated proteins with reduced coagulant activity 
(4). They are collectively referred to as PIVKAs (proteins induced by vitamin K 
absence/antagonism), and individual coagulation factors as PIVKA-number 
(e.g. PIVKA-II ) (5)(6).  
          Carboxylation promotes binding of the vitamin K–dependent 
coagulation factors to phospholipid surfaces, thereby accelerating blood 
coagulation . Carboxylation requires the reduced form of vitamin K (vitamin 
KH2). Coumarins block the formation of vitamin KH2 by inhibiting the enzyme 
vitamin K epoxide reductase, thereby limiting the carboxylation of the vitamin 
K–dependent coagulant proteins. In addition, the vitamin K antagonists inhibit 
carboxylation of the regulatory anticoagulant proteins C and S. The 
  
 
 
anticoagulant effect of coumarins can be overcome by low doses of vitamin K1 
(phytonadione) because vitamin K1 bypasses vitamin K epoxide reductase 
.Patients treated with large doses of vitamin K1 (usually >5 mg) can become 
resistant to warfarin for up to a week because vitamin K1 accumulating in the 
liver is available to bypass vitamin K epoxide reductase (4).  
           Warfarin also interferes with the carboxylation of Gla proteins 
synthesized in bone .Although these effects contribute to fetal bone 
abnormalities when mothers are treated with warfarin during pregnancy , there 
is no evidence that warfarin directly affects bone metabolism when 
administered to children or adults (4).  
 
Pharmacokinetics and Pharmacodynamics of Warfarin  
          Warfarin is a racemic mixture of 2 optically active isomers, the R and S 
forms, in roughly equal proportion. It is rapidly absorbed from the 
gastrointestinal tract, has high bioavailability, and reaches maximal blood 
concentrations in healthy volunteers 90 minutes after oral administration. 
Racemic warfarin has a half-life of 36 to 42 hours, circulates bound to plasma 
proteins (mainly albumin), and accumulates in the liver, where the 2 isomers are 
metabolically transformed by different pathways .The relationship between the 
dose of warfarin and the response is influenced by genetic and environmental 
  
 
 
factors, including common mutations in the gene coding for cytochrome P450, 
the hepatic enzyme responsible for oxidative metabolism of the warfarin S-
isomer. Several genetic polymorphisms in this enzyme have been described that 
are associated with lower dose requirements and higher bleeding complication 
rates compared with the wild-type enzyme CYP2C9.  
             In addition to known and unknown genetic factors, drugs, diet, and 
various disease states can interfere with the response to warfarin (4).  
Drug interaction (appendix3) 
           Drugs may influence the pharmacokinetics of warfarin by reducing 
gastrointestinal absorption or disrupting metabolic clearance. For example, the 
anticoagulant effect of warfarin is reduced by cholestyramine, which impairs its 
absorption, and is potentiated by drugs that inhibit warfarin clearance through 
stereoselective or nonselective pathways. Stereoselective interactions may affect 
oxidative metabolism of either the S - or R - isomer of warfarin. Inhibition of S-
warfarin metabolism is more important clinically because this isomer is 5 times 
more potent than the R-isomer as a vitamin K antagonist.                    
Phenylbutazone, sulfinpyrazone, metrnidazole, and trimethoprim-
sulfamethoxazole inhibit clearance of S-warfarin, and each potentiates the effect 
of warfarin on the prothrombin time (PT). In contrast, drugs such as cimetidine 
and omeprazole, which inhibit clearance of the R-isomer, potentiate the PT only 
  
 
 
modestly in patients treated with warfarin. Amiodarone inhibits the metabolic 
clearance of both the S - and R - isomers and potentiates warfarin 
anticoagulation . The anticoagulant effect is inhibited by drugs like barbiturates, 
rifampicin, and carbamazepine, which increase hepatic clearance.  Chronic 
alcohol consumption has a similar potential to increase the clearance of 
warfarin, but ingestion of even relatively large amounts of wine has little 
influence on PT in subjects treated with warfarin (4).  
            Drugs may influence the pharmacodynamics of warfarin by inhibiting 
synthesis or increasing clearance of vitamin K– dependent coagulation factors 
or by interfering with other pathways of hemostasis. The anticoagulant effect of 
warfarin is augmented by the second-and third-generation cephalosporins, 
which inhibit the cyclic interconversion of vitamin K ; by thyroxine, which 
increases the metabolism of coagulation factors ; and by clofibrate, through an 
unknown mechanism . Doses of salicylates >1.5 g per day and acetaminophen  
also augment the anticoagulant effect of warfarin, possibly because these drugs 
have warfarin-like activity . Heparin potentiates the anticoagulant effect of 
warfarin but in therapeutic doses produces only slight prolongation of the PT 
(4).  
            Drugs such as aspirin, non steroidal anti inflammatory drugs , penicillins 
(in high doses) , and moxolactam  increase the risk of warfarin-associated 
bleeding by inhibiting platelet function. Of these, aspirin is the most important 
  
 
 
because of its widespread use and prolonged effect. Aspirin and non steroidal 
anti inflammatory drugs also can produce gastric erosions that increase the risk 
of upper gastrointestinal bleeding. The risk of clinically important bleeding is 
heightened when high doses of aspirin are taken during high-intensity warfarin 
therapy (international normalized ratio [INR] 3.0 to 4.5). In 2 studies, one 
involving patients with prosthetic heart valves  and the other involving 
asymptomatic individuals at high risk of coronary artery disease , low doses of 
aspirin (100 mg and 75 mg daily, combined with moderate-and low-intensity 
warfarin anticoagulation, respectively also were associated with increased rates 
of minor bleeding (4).  
                The mechanisms by which erythromycin and some anabolic 
steroids potentiate the anticoagulant effect of warfarin are unknown. 
Sulfonamides and several broad- spectrum antibiotic compounds may 
augment the anticoagulant effect of warfarin in patients consuming diets 
deficient in vitamin K by eliminating bacterial flora and aggravating vitamin 
K deficiency (4).  
Warfarin - Food interactions 
           Green leafy vegetables are among the best food source of vitamin 
K .The average intake of vitamin K for adults in UK is 70-80 micrograms (mcg) 
per day. The Daily Value for vitamin K ,an estimate of daily need ,is 80 
  
 
 
micrograms. It is important to limit intake of food that provides more than 60% 
of the Daily Value for vitamin K to help to keep PT/INR in the desired range 
(10). 
           Subjects receiving long-term warfarin therapy are sensitive to 
fluctuating levels of dietary vitamin K, which is derived predominantly from 
phylloquinones in plant material. The phylloquinone content of a wide range of 
foodstuffs has been listed by Sadowski and associates. Phylloquinones 
counteract the anticoagulant effect of warfarin because they are reduced to 
vitamin KH2 through the warfarin-insensitive pathway. Important fluctuations in 
vitamin K intake occur in both healthy and sick subjects. Increased intake of 
dietary vitamin K sufficient to reduce the anticoagulant response to warfarin 
occurs in patients consuming green vegetables or vitamin K– containing 
supplements while following weight-reduction diets and in patients treated with 
intravenous vitamin K supplements. Reduced dietary vitamin K1 intake 
potentiates the effect of warfarin in sick patients treated with antibiotics and 
intravenous fluids without vitamin K supplementation and in states of fat 
malabsorption. Hepatic dysfunction potentiates the response to warfarin through 
impaired synthesis of coagulation factors. Hypermetabolic states produced by 
fever or hyperthyroidism increase warfarin responsiveness , probably by 
increasing the catabolism of vitamin K – dependent coagulation factors (4).  
 
  
 
 
Food high in vitamin K (more than or equal 200%  DV)(10)   
 Eat no more than 1 servings /day. 
A cup equals 8 ounces or ½ pound. 
Food     Serving size  %Daily value 
Kale ,fresh , boiled           1/2 cup            660 
Spinach,fresh,boiled          1/2 cup             560 
Turnip,green,boiled          1/2 cup             530 
Collards, fresh, boiled          1/2 cup 520 
Swiss chard, fresh ,boiled 1/2 cup 360 
Parsley,raw 1/4 cup 300 
Mustard green, fresh 
,boiled 
1/2 cup 260 
 
 
 
 
  
 
 
Food moderately high in vitamin K (60-199% DV) (10) 
        Eat no more than 3 servings /day 
Brussels sprouts, frozen or boiled ½ cup 190 
Spinach,raw 1 cup 180 
Turnip,greens,raw,chopped 1 cup 170 
Gree leaf lettuce,shredded 1 cup 125 
broccoli,raw,chopped 1 cup 110 
Endive lettuce,raw 1 cup 70 
Romaine lettuce,raw 1 cup 70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Indications for warfarin therapy: 
 
        The Indications for warfarin according to the Fourth  
American College of Chest Physicians (ACCP) Consensus 
Conference and product labeling for Coumadinare are as follows: 
 
(1) Prophylaxis and/or treatment of venous thrombosis and its   extension, and 
pulmonary embolism; 
  
(2) Prophylaxis and/or treatment of thromboembolic complications associated 
with atrial fibrillation and/or cardiac valve replacement; 
 
(3) Reducing the risk of death, recurrent myocardial infarction, and  
thromboembolic events such as stroke or systemic embolization after 
myocardial infarction (3). 
 
 
 
 
 
  
 
 
Goals of Anticoagulation:  
 
           The goal of anticoagulant therapy is to administer the lowest possible 
dose of anticoagulant to prevent clot formation or expansion. The required 
degree of anticoagulation continues to evolve as studies provide more 
information about the efficacy and safety of lower doses. Current therapeutic 
goals for various disease states are summarized in Table 1(11-16) 
  
Recommended Therapeutic Goal for Oral Anticoagulation: 
Indication Range of INR Duration 
Prophylaxis of venous 
thrombosis for high-risk 
surgery 
2-3  clinical judgment 
Treatment of venous 
thrombosis 
First episode
 
 
 
 
2-3 
 
 
 
3-6 months 
High risk of recurrent 
thrombosis 
2-3 Lifelong 
Thrombosis associated 3-4 Lifelong 
  
 
 
with antiphospholipid 
antibody 
Treatment of pulmonary 
embolism 
First episode
 
 
 
 
2-3 
 
 
 
3-6 months* 
High risk of recurrent 
embolism 
2-3 Lifelong 
Prevention of systemic 
embolism
Tissue heart  valves
 
 
 
2-3 
 
 
3 months 
Acute myocardial 
infarction (to prevent 
systemic embolism)†
2-3 Clinical judgment 
Valvular heart disease 
(after thrombotic event 
or if the left atrium is 
greater than 5.5 cm)
2-3 Lifelong 
Atrial fibrillation 2-3 Lifelong 
  
 
 
Chronic or intermittent
 
Cardioversion 2-3 3 weeks before and 4 
weeks after atrial 
fibrillation if normal 
sinus rhythm is 
maintained
Prosthetic heart valves
Aortic position 
  Mechanical 
 
2.5 -3.5‡ Lifelong
Bioprosthetic 2-3 Clinical judgment (3 
months optional)
Mitral position
Mechanical
 
2.5 -3.5‡ Lifelong
Bioprosthetic 2-3 3months
*--One study suggested that 4 weeks may be an adequate duration of oral 
anticoagulant therapy in patients without continuing risk factors.  
  
 
 
†--If oral anticoagulant therapy is elected to prevent recurrent myocardial 
infarction, an INR of 2.5 to 3.5 is recommended.  
‡--Depending on the type of mechanical valve (i.e., caged ball or caged disk) 
and the valve position (mitral), some patients may benefit from INRs in the 
upper end of the range. 
 
 
 
Laboratory monitoring of warfarin therapy 
 
         Measuring the prothrombin time (PT) remains the primary 
mechanism by which warfarin anticoagulation is monitored. Prolongation of the 
PT, however, depends on the responsiveness of the thromboplastin used to 
initiate coagulation. Hence, the WHO has currently established and 
international standard by which manufacturers or individual labs can determine 
an international sensitivity index (ISI) for each lot of thromboplastin. A 
therapeutic range of PT is then defined by the international normalized ratio 
(INR), which is the ratio between the patients PT to the mean normal PT for the 
lab raised to the power of the ISI: 
INR = (Patient PT/Mean Normal PT)ISI 
  
 
 
where the “mean normal PT” is the arithmetic mean prothrombin time for the 
laboratory .The ISI is a correction factor, specific for each lot of laboratory 
prothrombin reagent, that correlates the activity of the reagent to a standard 
maintained by the World Health Organization. A smaller ISI reflects a more 
sensitive thromboplastin reagent such that a more prolonged PT will be 
observed for the same therapeutic effect .In most medical institutions, the INR 
is automatatically calculated by the laboratory information system. The INR can 
also be calculated from the above formula or derived from an INR nomogram 
(2). 
          The dosing of warfarin is driven by monitoring the prothrombin time to 
achieve a PT in the appropriate therapeutic range .Typically 5 to 10 mg of 
warfarin is administered daily with daily monitoring of the INR. The dose is 
changed gradually until therapeutic range is reached and then the INR is 
followed on a regular but less frequent basis. Adjustments in dosage should be 
based on the weekly dose since warfarin has a long half-life. For most 
indications the INR should be maintained between 2.0 to 3.0. Exceptions 
include anticoagulation in patients with mechanical prosthetic heart valves and 
patients with the antiphospholipid antibody syndrome, in which the INR is 
usually kept between 2.5 and 3.5. However, it must be remembered that the INR 
was developed for deep venous thrombosis prophylaxis and may not be the 
most appropriate monitoring mechanism for other situations. Furthermore, 
  
 
 
inhibitors such as lupus anticoagulants can prolong the PT obscuring the 
appropriate therapeutic range such that it may be necessary to use alternative 
assays such as the direct quantitation of the plasma warfarin concentration (2).  
 
 
Complication of warfarin therapy 
Hemorrhagic Complications  
The most common complication of warfarin therapy is bleeding, which 
occurs in 6 to 39 percent of recipients annually. The incidence of bleeding is 
directly related to the intensity of anticoagulation. With the reductions in 
anticoagulation intensity that have evolved over the past 20 years, the incidence 
of hemorrhagic complications has decreased dramatically. In patients receiving 
warfarin therapy, the median annual rate of major bleeding ranges from 0.9 to 
2.7 percent, and the median annual rate of fatal bleeding ranges from 0.07 to 0.7 
percent (17). The incidence of complications varies within the ranges, 
depending on the clinical indication and the intensity of anticoagulation. 
Intracranial hemorrhage accounts for approximately 2 percent of the reported 
hemorrhagic complications of warfarin therapy and is associated with a 
mortality rate of 10 to 68 percent .Patient characteristics associated with a major 
risk of hemorrhage have been identified in a number of randomized studies 
  
 
 
.Bleeding that occurs with an INR of less than 3 is often associated with an 
underlying occult gastrointestinal or renal lesion. Risk of bleeding is augmented 
if the INR is out of range (due to accidental or deliberate overdose or due to 
interactions), and may cause hemoptysis (coughing up blood), excessive 
bruising, bleeding from nose or gums, or blood in urine or stool. 
The risks of bleeding is increased when warfarin is combined with 
antiplatelet drugs such as clopidogrel, aspirin, or other nonsteroidal anti-
inflammatory drugs (18). The risk may also be increased in elderly patients (19) 
and in patients on hemodialysis (20).  
WARFARIN NECROSIS  
A rare but serious complication resulting from treatment with warfarin is 
warfarin necrosis, which occurs more frequently shortly after commencing 
treatment in patients with a deficiency of protein C. Protein C is an innate 
anticoagulant that, like the procoagulant factors that warfarin inhibits requires 
vitamin K-dependent carboxylation for its activity. Since warfarin initially 
decreases protein C levels faster than the coagulation factors, it can 
paradoxically increase the blood's tendency to coagulate when treatment is first 
begun (many patients when starting on warfarin are given heparin in parallel to 
combat this), leading to massive thrombosis with skin necrosis and gangrene of 
  
 
 
limbs. Its natural counterpart, purpura fulminans, occurs in children who are 
homozygous for certain protein C mutations (21) 
OSTEOPOROSIS 
After initial reports that warfarin could reduce bone mineral density, 
several studies have demonstrated a link between warfarin use and osteoporosis-
related fracture. A 1999 study in 572 women taking warfarin for deep venous 
thrombosis, risk of vertebral fracture and rib fracture was increased; other 
fracture types did not occur more commonly (22).  A 2002 study looking at a 
randomly selected selection of 1523 patients with osteoporotic fracture found no 
increased exposure to anticoagulants compared to controls, and neither did 
stratification of the duration of anticoagulation reveal a trend towards 
fracture(23). 
          A 2006 retrospective study of 14,564 Medicare recipients showed that 
warfarin use for more than one year was linked with a 60% increased risk of 
osteoporosis-related fracture in men; there was no association in women. The 
mechanism was thought to be a combination of reduced intake of vitamin K, 
which is necessary for bone health, and inhibition by warfarin of vitamin K-
mediated carboxylation of certain bone proteins, rendering them nonfunctional 
(24). 
 
  
 
 
PURPLE TOE SYNDROME 
           Another rare complication that may occur early during warfarin 
treatment (usually within 3 to 8 weeks) is purple toe syndrome. This condition 
is thought to result from small deposits of cholesterol breaking loose and 
flowing into the blood vessels in the skin of the feet, which causes a bluish 
purple color and may be painful. It is typically thought to affect the big toe, but 
it affects other parts of the feet as well, including the bottom of the foot (plantar 
surface). The occurrence of purple toe syndrome may require discontinuation of 
warfarin (25).  
 
Contraindications: 
PREGNANCY 
          Warfarin is contraindicated in pregnancy, as it passes through the 
placental barrier and may cause bleeding in the fetus; warfarin use during 
pregnancy is commonly associated with spontaneous abortion, stillbirth, 
neonatal death, and preterm birth (26). Coumarins (such as warfarin) are also 
teratogens, that is, they cause birth defects; the incidence of birth defects in 
infants exposed to warfarin in utero appears to be around 5%, although higher 
figures (up to 30%) have been reported in some studies (27). Depending on 
  
 
 
when exposure occurs during pregnancy, two distinct combinations of 
congenital abnormalities can arise (26). 
            When warfarin (or another coumarin derivative) is given during the first 
trimester—particularly between the sixth and ninth weeks of pregnancy—a 
constellation of birth defects known variously as fetal warfarin syndrome 
(FWS), warfarin embryopathy, or coumarin embryopathy can occur. FWS is 
characterized mainly by skeletal abnormalities, which include nasal hypoplasia, 
a depressed or narrowed nasal bridge, scoliosis, and calcifications in the 
vertebral column, femur, and heel bone which show a peculiar stippled 
appearance on X-rays. Limb abnormalities, such as brachydactyly (unusually 
short fingers and toes) or underdeveloped extremities, can also occur (26) 
(27).Common non-skeletal features of FWS include low birth weight and 
developmental disabilities (26) (27). 
           Warfarin administration in the second and third trimesters is much less 
commonly associated with birth defects, and when they do occur, are 
considerably different from fetal warfarin syndrome. The most common 
congenital abnormalities associated with warfarin use in late pregnancy are 
central nervous system disorders, including spasticity and seizures, and eye 
defects (26) (27). 
  
 
 
              Anticoagulation therefore poses a problem in pregnant women 
requiring warfarin for vital indications, such as stroke prevention in those with 
artificial heart valves. Usually, warfarin is avoided in the first trimester, and a 
low molecular weight heparin such as enoxaparin is substituted; the risk of 
maternal hemorrhage with heparin is high and preterm birth  and stillbirth may 
still occur but heparins does not cross the placental barrier and therefore does 
not cause birth defects. Various solutions exist for the time around delivery.  
 
 
Management of Patients with High INR Values 
 
          There is a close relation between the INR and risk of bleeding. The 
risk of bleeding increases when the INR exceeds 4, and the risk rises sharply 
with values >5. Three approaches can be taken to lower an elevated INR. The 
first step is to stop warfarin; the second is to administer vitamin K1; and the 
third and most rapidly effective measure is to infuse fresh plasma or 
prothrombin concentrate. The choice of approach is based largely on clinical 
judgment because no randomized trials have compared these strategies with 
clinical end points. After warfarin is interrupted, the INR falls over several days 
(an INR between 2.0 and 3.0 falls to the normal range 4 to 5 days after warfarin 
  
 
 
is stopped) . In contrast, the INR declines substantially within 24 hours after 
treatment with vitamin K 1 (3).  
         Even when the INR is exceedingly high, the absolute daily risk of 
bleeding is low, leading many physicians to manage patients with INR levels as 
high as 5 to 10 by stopping warfarin expectantly, unless the patient is at 
intrinsically high risk of bleeding or bleeding has already developed. Ideally, 
vitamin K1 should be administered in a dose that will quickly lower the INR 
into a safe but not sub therapeutic range without causing resistance once 
warfarin is reinstated or exposing the patient to the risk of anaphylaxis. Though 
effective, high doses of vitamin K1 (eg, 10 mg) may lower the INR more than 
necessary and lead to warfarin resistance for up to a week. Vitamin K1 can be 
administered intravenously, subcutaneously, or orally. Intravenous injection 
produces a rapid response but may be associated with anaphylactic reactions, 
and there is no proof that this rare but serious complication can be avoided by 
using low doses. The response to subcutaneous vitamin K1 is unpredictable and 
sometimes delayed .In contrast, oral administration is predictably effective and 
has the advantages of convenience and safety over parenteral routes. In patients 
with excessively prolonged INR values, vitamin K1,1 mg to 2.5 mg orally, more 
rapidly lowers the INR to <5 within 24 hours than simply withholding warfarin 
.In a prospective study of 62 warfarin-treated patients with INR values between 
4 and 10, warfarin was omitted, and vitamin K1,1 mg, was administered orally 
  
 
 
.After 24 hours, the INR was lower in 95%, <4 in 85%, and <1.9 in 35%. None 
displayed resistance when warfarin was resumed. These observations indicate 
that oral vitamin K1 in low doses effectively reduces the INR in patients treated 
with warfarin. Oral vitamin K1, 1.0 to 2.5 mg, is sufficient when the INR is 
between 4 and 10, but larger doses (5 mg) are required when the INR is >10 (3).  
       Oral vitamin K1 is the treatment of choice unless very rapid reversal of 
anticoagulation is critical, when vitamin K1 can be administered by slow 
intravenous infusion (5 to 10 mg over 30 minutes). In 2001, the American 
College of Chest Physicians published the following recommendations for 
managing patients on coumarin anticoagulants who need their INRs lowered 
because of either actual or potential bleeding (3):  
1. When the INR is above the therapeutic range but <5, the patient has not 
developed clinically significant bleeding, and rapid reversal is not 
required for surgical intervention, the dose of warfarin can be reduced or 
the next dose omitted and resumed (at a lower dose) when the INR 
approaches the desired range.  
2. If the INR is between 5 and 9 and the patient is not bleeding and has no 
risk factors that predispose to bleeding, the next 1 or 2 doses of warfarin 
can be omitted and warfarin reinstated at a lower dose when the INR falls 
into the therapeutic range. Alternatively, the next dose of warfarin may be 
  
 
 
omitted and vitamin K1 (1 to 2.5 mg) given orally. This approach should 
be used if the patient is at increased risk of bleeding.  
3. When more rapid reversal is required to allow urgent surgery or dental 
extraction, vitamin K1 can be given orally in a dose of 2 to 5 mg, 
anticipating reduction of the INR within 24 hours. An additional dose of 
1 or 2 mg vitamin K can be given if the INR remains high after 24 hours.  
4. If the INR is >9 but clinically significant bleeding has not occurred, 
vitamin K1, 3 to 5 mg, should be given orally, anticipating that the INR 
will fall within 24 to 48 hours. The INR should be monitored closely and 
vitamin K repeated as necessary.  
5. When rapid reversal of anticoagulation is required because of serious 
bleeding or major warfarin over-dose (eg, INR >20), vitamin K1 should 
be given by slow intravenous infusion in a dose of 10 mg, supplemented 
with transfusion of fresh plasma or prothrombin complex concentrate, 
according to the urgency of the situation. It may be necessary to give 
additional doses of vitamin K1 every 12 hours.  
6. In cases of life-threatening bleeding or serious warfarin overdose, 
prothrombin complex concentrate re-placement therapy is indicated, 
supplemented with 10 mg of vitamin K1 by slow intravenous infusion; 
this can be repeated, according to the INR. If warfarin is to be resumed 
  
 
 
after administration of high doses of vitamin K, then heparin can be given 
until the effects of vitamin K have been reversed and the patient again 
becomes responsive to warfarin  
7.  
Warfarin booklet 
         Warfarin is a useful medicine that helps many patients. It can be 
dangerous when not used correctly or without proper medical attention. 
Warfarin booklet will help patients to take their warfarin correctly and 
safely. It answers common questions patients ask about warfarin {(suggested 
booklet (appendix4)}. 
          Every patient read the warfarin booklet should be able to know: 
Why  he takes warfarin. 
How to take warfarin. 
What dose he needs. 
When he needs to see the doctor. 
How warfarin can affect his lifestyle. 
         After the patient read the book, he should talk with the pharmacist or 
warfarin educator at the hospital. Once the patient  leaves the hospital,  the 
doctor or  the local pharmacist can help to  answer  patients questions about 
warfarin. 
  
 
 
General objective: 
To assess the control of warfarin therapy in patients attending anticoagulation 
clinic in the cardiac surgery and renal transplant center in Ahmed Ghasim 
Hospital. 
  
Specific objectives: 
1. To identify different factors that affect control of warfarin therapy in 
these patients. 
2. To determine level of knowledge of these patient regarding warfarin 
therapy. 
3. To generate guidelines of warfarin therapy in Sudanese patients. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
Study design 
 This is a descriptive retrospective cross sectional study. 
Study area: 
           The study area is the cardiac surgery and renal transplant center at 
Ahmed Ghasim Hospital that lies in Khartoum North, this center was opened in 
1998.It contains hundred beds.1812 open heart surgery were done in the period 
from 1998-2009. 
         Anticoagulation clinic was opened in 2008, about 250-320 patients are 
seen in the clinic per months. It is run by medical officers who are covered by 
physicians , it is follow up clinic for warfarin therapy. 
The center divisions: 
1. Catheter lab. 
2. Theatre. 
3. Two intensive care units. 
4. Two wards. 
5. Haemodialysis unit. 
  
 
 
6. Pharmacy. 
7. Clinical pharmacy unit. 
8. Therapeutic drug monitoring unit. 
9. X-ray unit 
10. Echo lab 
11. Referral clinics 
12. A laboratory, which covers investigation in hematology, clinical 
chemistry,histopathology,there is 17 technicians and a histopatholgist. 
13. Anticoagulation clinic 
Subjects: 
Subjects were one hundred cardiac patients on warfarin therapy attending the 
warfarin clinic in the cardiac surgical center. 
Controls: 
Control blood samples were obtained from working staff, all apparently healthy. 
Procedure: 
          A questionnaire was designed to include all the needed 
information(Appendix1). All individuals in the study were subjected to an oral 
  
 
 
interview after oral consent, they were asked direct questions concerning their 
illness, their knowledge about warfarin, any difficulties facing their warfarin 
therapy, the occurrence of complications, and the last INR. 
Blood sampling: 
          Blood samples were collected in the morning at 9:00-10:00am.After 
cleaning the site with a cotton pad soaked in dilute alcohol, using a 5 ml 
disposable syringe blood was collected in trisodium citrate dihydrate containers 
(9 volumes of blood to 1 volume of trisodium citrate dihydrate). 
Laboratory analysis: 
Analysis of the samples was done at the cardiac surgical center using 
coagulometer (Diamed CD4). 
Methods of analysis: 
Prothrombin time (PT) analysis: 
Semi automated method using coagulometer (Diamed CD4). 
Principles of measurement :  
            Diamed CD4 is a highly sensitive 4 channel photometer. A fifth channel 
controls the transmitter, which ensures accurate and precise results. For clot and 
chromogenic based tests. A standard filter of 405nm is provided. The Diamed 
  
 
 
CD4can detect  light absorbance up to2.5OD(optical density) with a resolution 
of 0.001OD(=E (Extinction)=unit of light absorbance) 
Turbidity method (clotting method) 
          The thrombin catalyzed conversion of fibrinogen to fibrin is the final 
reaction in the coagulation cascade .Fibrin formation results in an increase in 
sample turbidity which is detected by the photometer. Photometric detection is 
started manually by pressing the optic key with simultaneous addition of the test 
reagent .Alternatively, the reaction is started by the addition of the sample using 
the Autopipette .The time between the start of the photometric  detection , and 
the turning point of the reaction curve is the result. The result is displayed in 
seconds on the liquid crystal display and printed automatically to the thermal 
printer(appendix 2). 
 
 
 
 
 
 
  
 
 
 
Table (4.1): 
 
Indications for warfarin therapy in the patients studied: 
Indication for warfarin Frequency Percentage 
Prosthetic valves 77 77 
Congenital heart  disease 1 1 
Rheumatic heart disease 15 15 
Dilated cardiomyopathy 7 7 
Total 100 100 
 
 
  
 
 
 
Table (4.2): 
Time of warfarin administration in the patients studied: 
Time of warfarin 
administration 
Frequency Percentage 
In the morning 6 6 
Midday  1 1 
Evening 88 88 
At any time during the 
day 
5 5 
Total 100 100 
 
  
 
 
 
Table (4.3): 
Last INR investigation in the patients studied: 
Last INR Frequency Percentage 
Within the  therapeutic 
range 
44 44 
Below the therapeutic 
range 
36 36 
 Above the therapeutic 
range 
20 20 
Total 100 100 
 
 
 
 
 
 
  
 
 
 
Table (4.4): 
Difficulties in taking warfarin in the patients studied: 
Difficulties Frequency Percentage 
Not available in the 
nearby pharmacy 
6 6 
Expensive 10 10 
Difficult to obtain the 
exact dose 
1 1 
Residence far away from 
the  laboratories and 
hospitals 
29 29 
Expensive and far 
residence 
3 3 
No difficulty 50 50 
Total 100 100 
 
  
 
 
 
 
Table (4.5): 
 Number of patients having warfarin booklets in the population studied: 
Warfarin Booklets 
 
No. of patients Percentage 
Patients having warfarin 
booklets 
 
2 2 
Patients  not having 
warfarin booklets 
 
98 98 
Total 100 100 
 
  
 
 
 
Table (4.6): 
Patient knowledge about warfarin in the population studied: 
 Knows Doesn’t know Total 
What is warfarin 90 10 100 
Indication of 
warfarin 
44 56 100 
Diet containing 
Vitamin K 
88 12 100 
interaction 
between warfarin 
and antibiotics 
42 58 100 
interaction 
between warfarin 
and aspirin 
47 53 100 
 
  
 
 
 
Table (4.7): 
Patient knowledge about warfarin tablets in the population studied: 
 Frequency Percentage 
Knows all types by its 
strength and colour 
20 20 
Knows all types by its 
colour only 
18 18 
Knows 2 types by its 
strenght and colour 
17 17 
Knows 2 types by its 
colour only 
2 2 
Knows 1 type by its 
srenght and colour 
8 8 
Knows 1 type by its 
colour only 
4 4 
Does not know 31 31 
Total 100 100 
 
 
 
 
 
 
  
 
 
Table (4.8): 
Knowledge among ladies in the patients studied about the effect of 
warfarin on pregnancy: 
Action Total Percentage 
To inform the doctor that 
I am on warfarin 
22 31.8 
To continue the same 
dose 
47 68.2 
Total 70 100 
 
  
 
 
 
 
Table (4.9): 
Effect of school education on control of INR in the patients studied: 
Last INR 
investigation 
illiterate 
No.      
(%) 
primary 
No.     
(%) 
intermediate 
No.     (%) 
Secondary 
No.    (%) 
postgraduate
No.    (%) 
Controlled 18 (37.5) 9   
(42.9) 
 
1    (50%) 10  (52.6) 5(55.6) 
Low 18 (37.5) 9   
(42.9) 
 
0     (0%) 6  (31.6) 3(33.3) 
High 12 (60.0) 3   
(14.3) 
1    (50%) 3  (15.8) 1(11.1) 
Total 48 (100) 21(100) 2     (50%) 19 (100) 9(100) 
 
P value 0.102  (not significant) 
  
 
 
Table (4.10) 
Occurrence of bleeding or thrombosis complications in the population 
studied: 
Complication No. of patients Percentage 
Bleeding 36 36 
Thrombosis 1 1 
No complication 63 63 
Total 100 100 
 
  
 
 
 
Table (4.11): 
Frequency of bleeding in the population studied: 
Frequency of bleeding Frequency Percentage 
Once 15 41.6 
Twice 8 22.2 
Several times 13 36.2 
Total 36 100 
 
  
 
 
 
Table (4.12) 
The sites of bleeding due to warfarin overdose in the population studied: 
Site No. of patients Percentage 
Epistaxis 15 41.7 
Gingival bleeding 9 25.0 
genitourinary bleeding 6 16.7 
Black stool 3 8.3 
Multiple sites  3 8.3 
Total 36 100 
  
 
 
  
 
 
 
  
 
 
  
 
 
 
 
  
 
 
  
  
 
 
 
 
  
 
 
 
Discussion 
           The different factors which affect proper warfarin control in one 
hundred patient taking warfarin for different indications were assessed at this 
study. The study population composed of 66 female and 34 male of different 
age groups .The results were compared to the results of a similar Sudanese 
study which was conducted at 2000 in the same hospital on a same number of 
patients (28). 
           It was noted that in our group of patients the most frequent indication for 
lifelong warfarin was prosthetic heart valves, in contrast to the previous 
Sudanese study which was rheumatic heart disease, this reflects  the increase in 
the number of operations ,and the opening of the of the warfarin clinic .  
          In our study 38% of the patients were properly controlled having an INR 
within the therapeutic range, in contrast to the previous study when the number 
is 34% , this is  again a small  number and as warfarin is a dangerous drug  and 
therefore  if it is prescribed it must be properly controlled.  
             20% of our patients had good level of education regarding warfarin, 
compared to 16% in the previous study  which means no significant change 
occurred after these 10 years ,  and this again a small number as warfarin is a 
  
 
 
serious drug and all patients must be fully educated before initiation of the 
therapy. 
         When we considered the elements of education we found that, 60% of our 
patients did not received education programme about warfarin, 71.4% of them 
were educated after starting the therapy,20% only knew the color and strength 
of the warfarin tablets compared to a similar Chinese study when the figure was 
40-45% (29). 
           60% of the patients were taking different medication with different 
interaction with warfarin.88% of the patients knew the different interaction of 
warfarin with different types of diet; this a good effort done by the nutrition unit 
which is a part of the warfarin clinic. 
           Other factors that affect warfarin control include financial and 
geographical factors.70% of the population studied live far from the center 
outside Khartoum state. 
            Booklets providing information about the drug and registering INR 
results are very important for the proper management of these patients but 
unfortunately only 2 of our patients were provided with the booklets, and they 
obtained it from another hospital. In the previous study 12 of the patients had 
the booklet and they obtain it from abroad; so in the previous 10 years, no 
booklets was provided from the hospital to the patients to improve their INR. In 
  
 
 
a similar Chinese study all the patients had  booklets and 49.2%had  read the 
information booklet on warfarin and had better knowledge than those who had 
not). Illiteracy was the main reason for not reading the booklets. There was a 
positive correlation between patients' warfarin knowledge and the number of 
INR values that were within the target range in the 4 most recent clinic 
visits(29). 
            36% of our patients suffer from bleeding, the commonest site being the 
nose in the form of epistaxis; 36.2% from them have bleeding for several times, 
this is a large number as only 12% of the patients had bleeding in the previous 
study. This reflects the bad control as 33% of our patients have prolonged INR, 
compared to one patient in the previous study. These figures are higher than 
those reported in the literature in patients receiving warfarin therapy. The 
median annual rate of major bleeding ranged from 0.9 to 2.7 percent, and the 
median annual rate of fatal bleeding ranged from 0.07 to 0.7 percent (17).                           
          Regarding thrombosis only 2 of our patients suffered from one attack of 
cerebral thrombosis in the form of cerebrovascular accident, in contrast to one 
patient in the previous study. 
              School education did not seem to affect warfarin control since in both 
educated and illiterate patients, the percentage of those who have controlled 
INR are similar.  
  
 
 
            In our study the optimum maintainace dose was found to be 3-
5mg.report in the literature have given figures of 4-6 mg (30).   
 
  
 
 
 
Conclusion 
 
           From this study it was concluded after 10 years that more than half of the 
patients were not well controlled having an INR outside the therapeutic range. 
          It seems still after 10 years that the most significant causes of poor 
control are lack of full education about the drug and the far residence from 
hospital and laboratories and the high cost of the INR investigation. 
         Unfortunately after 10 years more complications occur to the patients, 
bleeding endangers a large number of our patients life. Thrombosis still seems 
to be a rare complication.  
  
 
  
 
 
 
Recommendations 
 
1. All patients should have full education about warfarin before initiating 
the therapy. 
2. Methods of education like personalized patient education,group 
discussion, warfarin booklets, videotapes should be available to patients 
at the center. 
3. To provide more centers for follow up of INR investigation especially 
outside Khartoum state. 
4. To solve the financial problems facing warfarin therapy, the cost of the 
therapy and the investigation. 
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ﻢﺴﺑ ﷲا ﻦﻤﺣﺮﻟا ﻢﻴﺣﺮﻟا  
The graduate college 
Medical and health studies board 
Serial No (   ) 
Name:………………………………………………………….. 
1. Sex :                  a. male            b. female 
2. Age: a.10-19  b. 20 29  c. 30-39 d. 40-49 e. 50-60 f>60 
3. Residence: a. near to the center b. far from the center 
4. Education:   a. illiterate     b. primary   c. intermediate d. secondary  e. 
graduate f. postgraduate 
5. Occupation: ..…………………………………………….. 
Patient warfarin therapy 
6. Indication for warfarin therapy 
7. Duration for warfarin therapy………………………………… 
8. Time of warfarin intake a. in the morning b. middy      c. evening   d. at 
any time during the day 
9. Dose of warfarin now…………………… 
10.1  No. of visit for  warfarin control: 
a. according to the doctor request       b. not regular 
10.2 if b. explain why?    
11.1 Dose the patient take any drug(s) other than warfarin?  
 a. yes      b. no 
11.2 . If (a) mention it( them)………………………………. 
12.1. Have you received education program about warfarin?  
a yes.       b. no 
12.2. If yes when ? 
     a. before initiation of warfarin    b. after  initiation of warfarin   
12.3 If yes where ?    a. private clinic.        b. hospital       c. abroad  
13.1 Have you warfarin booklet?   a. yes      b. no. 
13.2 If yes, from where did you obtain it? a. Sudan   b. abroad 
  
13.3 if yes are you taking it with you all the time? 
14. is there any difficulty in taking warfarin? 
a. not available in the nearby pharmacy 
b. expensive 
c. difficult to obtain the exact dose 
d. residence far away from the laboratories and hospitals 
e. other factors 
if ( e) mention these factors………………………………… 
The knowledge about warfarin 
15. what is warfarin?   a. knows   b.  does not know   
16.  why are you on warfarin? a. knows   b. does not knows   
17. what is the type of warfarin tablets and its colour? 
a. knows all types by its dose and colour 
b. knows all types its colour only 
c.  knows 2 types by its dose and colour 
d. knows 2 types  by its colour only 
e. . knows 1 types  by its dose and colour 
f. knows 1 types colour only 
g. does not know 
18.1 does the patient  knows diet containing vit k  ?   a. yes   b.no. 
 18.2 if yes mention few………………………….. 
19.1 does the patient  knows that there is interactions between warfarin 
and  
19.1 antibiotics       a. yes      b. no 
19.2 asprin             a. yes      b. no 
20. What the patient will do if he/she is ill and needs antibiotics? 
  
a. goes to a doctor and tell him he/she on warfarin 
b .goes to a doctor and tell him he/she on warfarin if asked 
c. gets antibiotics from the nearby pharmacy  
21. What the patient will do if he/she is ill and needs any surgical or 
dental operation? 
 a. To inform the doctor and tell him he/she on warfarin 
 b. To inform the doctor and tell him he/she on warfarin if asked 
22. question to married women 
If you get  pregnant what  to do?  
a. to inform the doc tor that I am on warfarin. 
b. to continue the same dose 
Warfarin complications 
23.1  Have you ever have bleeding while you are on warfarin? 
                a.   yes.           b.no 
23.2  If a When?............................................................................... 
23.3   where is are the site(s) of that bleeding ? …………………… 
23.4   How many time?       A. once          b. twice c.> twice 
24.1  Have you any thrombotic attack while you are on warfarin? 
 a. yes  b. no 
24.2  If yes when?.......................................................................... 
24.3  Where is/ are the site (s) that thrombosis ?......................... 
24.4   Number of thrombotic attacks ? a. once    b. twice c.> twice 
24.5  If © specify…………………………………………………… 
Investigations   
25. last INR investigations…………………………………………                
      
